

## 510(k) Summary

### 1. Submission Sponsor

Medusa Medical Technologies Inc.  
Suite 140-36 Solutions Dr  
Halifax, Nova Scotia  
B3S 1N2 Canada  
Phone: (902) 429-1200  
Fax: (902) 484-5583  
Contact: Craig Fraser, VP of Sales and Product Management

### 2. Submission Correspondent

Emergo Group, Inc.  
816 Congress Avenue, Suite 1400  
Austin, TX 78701  
Cell Phone: (561) 305-5075  
Office Phone: (512) 327-9997  
Fax: (512) 327-9998  
Contact: Diane Sudduth, Senior Consultant, QA  
Email: [project.management@emergogroup.com](mailto:project.management@emergogroup.com)

### 3. Date Prepared

May 2, 2013

### 4. Device Identification

Trade/Proprietary Name:	Medusa Medical Technologies, Inc. Siren ePCR Suite™
Common/Usual Name:	Siren ePCR
Classification Name:	Display, Cathode Ray Tube, Medical
Classification Regulation:	870.2450
Product Code:	DXJ; NSX
Device Class:	Class II
Classification Panel:	Cardiovascular; General Hospital

### 5. Predicate Devices

K103473 Zoll Medical Corporation - RescueNet ePCR

### 6. Device Description

Siren ePCR Suite™ is a software-only product. Siren ePCR Suite™ is a medical data collection system used to collect, store and print patient data that is entered by a user (caregiver), or captured from specified medical devices, and is integrated into a patient care report (patient

electronic medical record). Siren ePCR Suite™ is non-alarming software that runs on a variety of commercial off-the-shelf hardware.

## 7. Intended Use

Siren ePCR Suite™ is intended for the collection, storage and printing of patient data that is entered by a user (paramedics), or captured from specified medical devices, and integrated into a patient care report (patient electronic medical record). Siren ePCR Suite™ is intended for use by qualified medical personnel providing direct patient care in the pre-hospital environment to document the care provided. Siren ePCR Suite™ is indicated for use by health care providers whenever there is a need for generation of a patient record.

## 8. Comparison of Technological Characteristics

The following table compares the Siren ePCR Suite™ to the predicate device with respect to intended use, overall technological and functional characteristics, providing more detailed information regarding the basis for the determination of substantial equivalence.

The Siren ePCR Suite™ is similar in design and function to the predicate device for the modes of operation and use.

**Table 5A – Comparison of Characteristics**

<b>Manufacturer</b>	<b>Zoll Medical Corporation</b>	<b>Medusa Medical Technologies Inc.</b>
<b>Trade Name</b>	<b>Predicate RescueNet ePCR</b>	<b>New Device Siren ePCR Suite™</b>
<b>510(k) Number</b>	<b>K103473</b>	<b>Not assigned</b>
<b>Product Code</b>	<b>DJX NSX</b>	<b>DJX NSX</b>
<b>Regulation Number</b>	<b>870.2450 Null</b>	<b>870.2450 Null</b>
<b>Regulation Name</b>	<b>Display, Cathode Ray Tube, Medical</b>  Software, Transmission and Storage, Patient Data	<b>Display, Cathode Ray Tube, Medical</b>  Software, Transmission and Storage, Patient Data
<b>Indications for Use</b>	RescueNet ePCR is intended for the collection, storage and printing of patient data that is entered by a user (caregiver), or captured from specified medical devices, and integrated into a patient care report (patient electronic medical record).	Siren ePCR Suite™ is intended for the collection, storage and printing of patient data that is entered by a user (paramedic), or captured from specified medical devices, and integrated into a patient care report (patient electronic medical

<b>Manufacturer</b>	<b>Zoll Medical Corporation</b>	<b>Medusa Medical Technologies Inc.</b>
<b>Trade Name</b>	<b>Predicate RescueNet ePCR</b>	<b>New Device Siren ePCR Suite™</b>
	RescueNet ePCR is intended for use by qualified medical personnel providing direct patient care in the pre-hospital environment to document the care provided. RescueNet ePCR is indicated for use by health care providers whenever there is a need for generation of a patient record.	record). Siren ePCR Suite™ is intended for use by qualified medical personnel providing direct patient care in the pre-hospital environment to document the care provided. Siren ePCR Suite™ is indicated for use by health care providers whenever there is a need for generation of a patient record.
<b>Material</b>	Software	Software
<b>System Requirements</b>		
<b>Compatible operating system (software only)</b>	Windows XP Professional	Field User: Windows XP or XP Tablet Edition SP3 or Windows 7 SP1; SQL Express 2005 SP3  Server: Windows Server 2003 R2 SP3; SQL Server 2005 SP3 / SQL Server 2008 SP3 .NET Framework
<b>Web-Based Application (Locally installed vs. vendor server based)</b>	WebPCR module provides a web based access when connected to web browser or WebPCR server.	Web based Administration and Workflow. Store and forward communication from tablet to server.
<b>Hardware</b>		
<b>Compatibility and system requirements</b>		
<b>Desktop PC</b>	Yes	Yes
<b>Tablet PC</b>	Yes	Yes
<b>Pocket PC/Palm device compatible</b>	Yes	No
<b>Internet connection required at all time or only during data sync</b>	Only during data sync from mobile devices	Only during data sync from mobile devices
<b>Printer compatibility</b>	Yes, can print locally or across a network	Yes, can print locally or across a network
<b>Wireless access supported (ie Verizon/sprint WWAN)</b>	Yes	Yes

<b>Manufacturer</b>	<b>Zoll Medical Corporation</b>	<b>Medusa Medical Technologies Inc.</b>
<b>Trade Name</b>	<b><u>Predicate</u> RescueNet ePCR</b>	<b><u>New Device</u> Siren ePCR Suite™</b>
<b>Security</b>		
<b>Data encryption</b>	Yes	Yes
<b>Ability to lock PCR once completed</b>	Yes	Yes
<b>Tracks changes to module databases, including date, time, computer and user who made the change</b>	Yes	Yes
<b>Data Exchange</b>		
<b>Interface to server (Data synchronization)</b>	Yes, wireless or hard wired	Over internet connection
<b>Interface with CAD/Dispatch</b>	Yes	Yes
<b>Interface with Hospitals (Fax, email/etc., direct sync, etc.)</b>	Yes	Yes
<b>Interface with Hospital Pre-Alert</b>	Yes	Yes
<b>Interface with Billing</b>	Yes	Yes
<b>Interface with Medical Equipment</b>	<u>Physio-Control</u> LifePak 11 monitor/defibrillator, LifePak 12/15 monitor/defibrillator, LifePak 500 monitor/defibrillator; <u>Philips</u> HeartStart MRx; <u>Zoll</u> 1600, AED Plus/AED Pro, M Series/E Series	<u>Physio-Control</u> LifePak 12/15 monitor/defibrillator  <u>Philips</u> HeartStart MRx  <u>Zoll</u> M Series/E Series
<b>EKG Integration</b>	Yes	Yes
<b>Mobile-to-mobile data transfer</b>	Yes	Yes
<b>Interfaces to electronic record (EHR) / HL7</b>	Yes	Yes

<b>Manufacturer</b>	<b>Zoll Medical Corporation</b>	<b>Medusa Medical Technologies Inc.</b>
<b>Trade Name</b>	<b>Predicate RescueNet ePCR</b>	<b>New Device Siren ePCR Suite™</b>
<b>Additional Features</b>		
<b>Electronic Signature Support</b>	Yes	Yes
<b>Ability to link reference documents (protocols)</b>	Yes	Yes
<b>Ability to populate patient info from previous patient contact</b>	Yes	Yes
<b>Drug Monograph database</b>	No	Yes via integration with existing commercial drug monograph providers (MicroMedix)
<b>Use environment</b>	EMT, paramedic	EMT, paramedic
<b>Intended users (target population)</b>	Professional Users	Professional Users

## 9. Non-Clinical Testing

The device's software development, verification and validation have been carried out in accordance with the FDA's guidance documents. The software was tested against the established Software Design Specifications for each of the test plans to assure the device performs as intended.

The device Hazard analysis was completed and risk control implemented to mitigate hazards. The testing results supports that all specifications have met the acceptance criteria of each module and interaction of processes. Siren ePCR Suite™ device passed all testing and supports the claims of substantial equivalence and safe operation.

## 10. Clinical Testing

There was no clinical testing required to support the medical device as the indications for use is equivalent to the predicate device. These types of devices, including the predicate devices, have been on the market for many years with a proven safety and efficacy for the use of the device. The non-clinical testing detailed in this submission supports the substantial equivalence of the device.

## 11. Statement of Substantial Equivalence

By definition, a new device is substantially equivalent to a predicate device when the device has the same intended use as the previously cleared predicate device and either (i) the same technological characteristics as the predicate, or (ii) if the new device has different

technological characteristics, then those differences raise no new issues regarding the safety or effectiveness of the new device.

It has been shown in this 510(k) submission that Siren ePCR Suite™ has the same intended use as the predicate device and that any technological differences between the Siren ePCR Suite™ software and the predicate device do not raise any questions regarding Siren ePCR Suite™'s safety and effectiveness. Performance testing and compliance with voluntary standards demonstrate that Siren ePCR Suite™ software is substantially equivalent to the relevant aspects of the predicate device in terms of design, principals of operation, performance characteristics, and intended use. The Siren ePCR Suite™ software, as designed and manufactured, is determined to be substantially equivalent to the referenced predicate devices.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Center - WO66-G609  
Silver Spring, MD 20993-0002

January 3, 2014

Medusa Medical Technologies, Incorporated  
C/O Dr. Diane Sudduth  
Senior Consultant, QA  
Emergo Group, Incorporated  
816 Congress Avenue, Suite 1400  
Austin, TX 78701

Re: K131272

Trade/Device Name: Medusa Medical Technologies, Inc. Siren ePCR Suite  
Regulation Number: 21 CFR 870.2450  
Regulation Name: Medical Cathode-Ray Tube Display  
Regulatory Class: II  
Product Code: DXJ, NSX  
Dated: November 18, 2013  
Received: November 19, 2013

Dear Dr. Sudduth:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

**Mary S. Runner -S**

Erin I. Keith, M.S.  
Acting Director  
Division of Anesthesiology, General Hospital,  
Respiratory, Infection Control and  
Dental Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure



## Indications for Use Statement

**510(k) Number (if known):** K131272

**Device Name:** Siren ePCR Suite™

### Indications for Use:

Siren ePCR Suite™ is intended for the collection, storage and printing of patient data that is entered by a user (paramedic), or captured from specified medical devices, and integrated into a patient care report (patient electronic medical record). Siren ePCR Suite™ is intended for use by qualified medical personnel providing direct patient care in the pre-hospital environment to document the care provided. Siren ePCR Suite™ is indicated for use by health care providers whenever there is a need for generation of a patient record.

Prescription Use   x    
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use             
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)

Digitally signed by  
Richard C. Chapman  
Date: 2014.01.02  
11:33:26 -05'00'